Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Ally Financial
ALLY
5
Bank of America
BAC
CN Stock MarketDetailed Quotes
688767 Hangzhou Biotest Biotech
- 43.32
- -0.83-1.88%
Market Closed May 15 15:00 CST
4.62BMarket Cap33.32P/E (TTM)
44.48High43.20Low6.59KlotVolume44.16Open44.15Pre Close28.71MTurnover0.62%Turnover Ratio27.26P/E (Static)106.67MShares44.6052wk High1.91P/B4.62BFloat Cap22.8852wk Low52.98Limit Up106.67MShs Float146.02Historical High35.32Limit Down2.90%Amplitude20.95Historical Low1.30Dividend TTM43.57Avg Price3.72KlotAsk3.00%Div YieldTTM100Lot Size2.34KlotBid
Hangzhou Biotest Biotech News
Botuo Biotech 2024 Annual Report
Botuo Biotech 2024 Annual Report Summary
Botuo Biotech\'s 2025 First Quarter Report
Hangzhou Biotest Biotech Co.,Ltd.'s (SHSE:688767) Last Week's 17% Decline Must Have Disappointed Private Companies Who Have a Significant Stake
Wu Shujiang from Botao Bio: Focus on differentiated competition in the in vitro diagnostic Industry POCT subdivision, the commercialization of microfluidic testing products has arrived in its inaugural year | Dialogue with technology innovators.
① "Currently, microfluidic detection products have achieved technical breakthroughs, and customer feedback has been relatively positive." Microfluidic detection products will be the company's new generation of rapid diagnostic products handed over to the market. ② The company focuses on overseas markets, with overseas business accounting for 70%, and the North American and Latin American markets are growing rapidly.
Botao Biology (688767.SH): Deepseek has not been deployed yet.
On March 14, Gelonghui reported that Botuo Biomedical (688767.SH) stated on the interaction platform that the company has not yet deployed Deepseek. The company is closely monitoring the development trends of new technologies such as AI and is actively exploring the application and empowerment of AI and other new technologies in its Business and office.
Botuo Biotech: Botuo Biotech 2024 Annual Performance Report Announcement
Botuo Biotech 2024 Annual Results Report Announcement
Botao Biotechnology (688767.SH): Director and senior management personnel Gao Hongmei plans to reduce shareholding by no more than 0.56 million shares.
On February 6, Gelonghui reported that Botou Biotechnology (688767.SH) announced that it recently received a "Shareholding Reduction Plan Notification Letter" from Ms. Gao Hongmei, a Director and senior management personnel. Due to personal funding needs, Ms. Gao Hongmei intends to reduce her shareholding by no more than 560,000 shares through block trading or centralized bidding, which accounts for no more than 0.5250% of the company's total share capital. The reduction period will be within three months starting from 15 trading days after the announcement of this shareholding reduction plan.
Botuo Biotech: Botuo Biotech\'s 2024 annual results forecast
Botuo Biotech 2024 Annual Results Forecast
Botao Biotechnology (688767.SH): Net income is expected to increase by approximately 59.47% in 2024.
On January 23, Gelonghui reported that Botao Biotechnology (688767.SH) announced its annual earnings forecast for 2024. According to preliminary calculations by the finance department, it is expected that the net income attributable to the parent company's owners will be around 170 million yuan in 2024, an increase of approximately 59.47% year-on-year. The net income attributable to the parent company's owners after deducting non-recurring gains and losses is expected to be around 119 million yuan, an increase of approximately 49.83% year-on-year. The company continues to focus on the POCT in-vitro diagnostics sub-industry, effectively grasping customer needs and actively expanding domestic and international markets.
Bohuo Bio (688767.SH) will distribute 5 yuan for every 10 shares in the first three quarters, with the equity registration date on January 9.
Bote Biological (688767.SH) issued an announcement that the company will implement equity distribution for the first three quarters of 2024, with each share...
Net income sharply declined with the contraction of overseas sales, Botai Biology opens up the microfluidic testing field | Earnings conference
①The rapid decline in overseas income dragged down the performance of Botuo Life Sciences, with overall revenue significantly decreasing compared to before the epidemic, and net income attributable to shareholders has decreased year-on-year for multiple years; ② Considering changes in the external environment, Botuo Life Sciences has terminated two major core investment projects, added the Microfluidic Fluorescence Detection Platform project, and ventured into the microfluidic technology field.
Botuo Biotech Report for the Third Quarter of 2024
Botao Biology (688767.SH): Plans to launch an employee stock ownership plan in 2024.
Galaxy Comprehensive News September 25th | Botuo Biotechnology (688767.SH) announced the 2024 employee stock ownership plan, the stocks in this employee stock ownership plan come from the company's repurchase special account to repurchase Botuo Biotechnology A ordinary shares. The target stocks to be held in this employee stock ownership plan will not exceed 2.15 million shares, accounting for approximately 2.02% of the total 106.666667 million shares of the company's capital stock on the date the draft of this employee stock ownership plan was announced. The funds for this employee stock ownership plan come from legitimate employee compensation, self-raised funds, and other methods allowed by laws and regulations. The company does not provide financial assistance or loans to shareholders.
Hangzhou Biotest BiotechLtd's (SHSE:688767) Shareholders May Want To Dig Deeper Than Statutory Profit
Summary of Botuo Biotech\'s 2024 Semi-Annual Report
Botuo Biotech 2024 Semi-Annual Report
Biotrack (688767.SH) released its semi-annual performance, with a net income of 72.18 million yuan, a year-on-year increase of 17.16%.
Biotech (688767.SH) disclosed its 2024 interim report, during the reporting period the company achieved revenue of 2.67...
Market Insights
Warren Buffett Portfolio Warren Buffett Portfolio
Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.
Unlock Now
Discussing
Berkshire 2025 highlights: Stepping aside as CEO, trade and market volatility
$Berkshire Hathaway-A (BRK.A.US)$ held its highly anticipated annual shareholders meeting Saturday. Here are some key takeaways from the eve
Buffettttttt
May 3 21:00
Berkshire's 2025 Annual Shareholders Meeting